跳转到内容

CHK-336

维基百科,自由的百科全书
CHK-336
首选IUPAC名
2-[5-(cyclopropylmethyl)-3-(4-fluorophenyl)-4-[(3-fluoro-4-sulfamoylphenyl)methyl]pyrazol-1-yl]-1,3-thiazole-4-carboxylic acid
识别
CAS号 2743436-86-2
PubChem 162358463
ChemSpider 129432022
SMILES
 
  • NS(=O)(=O)C1=C(F)C=C(CC2=C(CC3CC3)N(N=C2C4=CC=C(F)C=C4)C5=NC(=CS5)C(O)=O)C=C1
性质
化学式 C24H20F2N4O4S2
摩尔质量 530.57 g·mol−1
若非注明,所有数据均出自标准状态(25 ℃,100 kPa)下。

CHK-336是一种含氟有机硫化合物,分子式C
24
H
20
F
2
N
4
O
4
S
2
,可作为乳酸脱氢酶小分子抑制剂,由诺华集团旗下的Chinook Therapeutics維基數據Q112085469研发,用于治疗高草酸尿症英语Hyperoxaluria[1]

参考文献

[编辑]
  1. ^ Cox, Jennifer H.; Boily, Marc-Olivier; Caron, Alex; Chefson, Amandine; Chong, Oliver; Ding, Jim; Dumais, Valerie; Gaudreault, Samuel; Gomez, Robert; Guthrie, James; Holmes, Ross P.; King, Andrew J.; Knight, John; Lester, Jeff; Lowther, W. T. Discovery of CHK-336: A First-in-Class, Liver-Targeted, Small Molecule Inhibitor of Lactate Dehydrogenase for the Treatment of Primary Hyperoxaluria: PO1620需要付费订阅. Journal of the American Society of Nephrology. October 2020, 31 (10S): 514. ISSN 1046-6673. doi:10.1681/ASN.20203110S1514a (英语).